Shield Therapeutics PLC Total Voting Rights Update (5313J)
29 Abril 2022 - 1:00AM
UK Regulatory
TIDMSTX
RNS Number : 5313J
Shield Therapeutics PLC
29 April 2022
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Total Voting Rights Update
London, UK, 29 April 2022: Shield Therapeutics plc (LSE: STX), a
commercial stage specialty pharmaceutical company with a focus on
addressing iron deficiency with its lead product Accrufer(R)
(ferric maltol), confirms that in accordance with the requirements
of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's
issued share capital consists of 216,192,462 ordinary shares of
1.5p each in issue, each with equal voting rights. No shares are
held in treasury.
The above figure may also be used by shareholders as the
denominator in the calculations by which they will determine
whether they are required to notify their interest, or a change to
their interest, in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Christopher Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Alice Lane/George
Dollemore +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR (UK Advisor)
Paul McManus/Lianne Applegarth/Alice +44 (0)20 7933 8780 or shield@walbrookpr.com
Woodings
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company
with a focus on addressing iron deficiency with its lead product
Accrufer(R)/Feraccru(R) (ferric maltol), a novel, stable, non-salt
based oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Accrufer(R)/Feraccru(R), has been
approved for use in the United States, European Union, UK,
Switzerland, and Australia and has exclusive IP rights until the
mid-2030s. The Group has recently launched Accrufer (R) in the US.
Feraccru(R) is being commercialised in the UK and European Union by
Norgine B.V., who also have the marketing rights in Australia and
New Zealand. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Accrufer(R)/Feraccru(R) in China, Hong Kong,
Macau, and Taiwan, Korea Pharma Co., Ltd. in the Republic of Korea
and with KYE Pharmaceuticals Inc in Canada.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRKDLBLLZLBBBF
(END) Dow Jones Newswires
April 29, 2022 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024